Q3 2025 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112378
$96.8M
Reported value
28
Positions
2025-09-30
Period end
The Brief · ACUTA CAPITAL PARTNERS, LLC · Q3 2025
AI · grounded in 13F
ACUTA CAPITAL PARTNERS, LLC closed its position in SLNO for a reduction of $5.3M. The fund established new positions in AMLX for $4.5M and CMPX for $2.9M. Other activity included closing positions in TRVI and HELIX ACQUISITION CORP II, while increasing its stake in DRUG by 75.09%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $13.6M | 14.1% | 1,165,206 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $13.6M | 14.0% | 141,529 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $12.8M | 13.3% | 268,451 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $6.5M | 6.70% | 3,410,402 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $5.6M | 5.74% | 38,592 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $5.1M | 5.32% | 84,875 | Common | SOLE |
| 04016X101 | ARGX | ARGEN SE - ADR | $4.7M | 4.86% | 6,379 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $4.5M | 4.68% | 333,258 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $3.8M | 3.90% | 502,797 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $3.3M | 3.42% | 25,114 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $2.9M | 3.04% | 840,090 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $2.6M | 2.72% | 49,751 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $2.3M | 2.38% | 178,415 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHA-ADR | $1.9M | 2.01% | 9,792 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $1.9M | 1.93% | 10,573 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $1.8M | 1.85% | 101,777 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.5M | 1.54% | 454,827 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $1.5M | 1.53% | 102,907 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $1.4M | 1.41% | 80,143 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $1.3M | 1.31% | 143,446 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $983,750 | 1.02% | 25,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $962,506 | 0.99% | 2,296 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $551,577 | 0.57% | 16,377 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $525,697 | 0.54% | 57,141 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $473,700 | 0.49% | 30,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $392,794 | 0.41% | 8,411 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $261,535 | 0.27% | 59,985 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC -CW27 | $18,357 | 0.02% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.